November 12th 2018; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today the appointment of Dr Shunsheng Zheng as Director of Business Development. Shunsheng has extensive knowledge of licensing and commercialization strategies for cancer drugs.
Prior to joining Celleron Therapeutics, Shunsheng was the principal investigator of a joint drug discovery programme at MSD and A*STAR Singapore. He did his post-doctoral training under Sir David P Lane FRS, the first Chief Scientist of Cancer Research UK and the co-discoverer of the p53 gene. Shawn was educated at the Universities of Oxford and Cambridge where he received his DPhil and MBA degrees respectively. He is a leading author in a number of top-tier scientific journals and a recipient of multiple prestigious scholarships.
“We are very pleased to be appointing Shunsheng to this key position as we build both our business and commercialisation operations to complement our advancing pipeline of drugs” commented CEO Prof Nick La Thangue.
About Celleron Therapeutics
Celleron Therapeutics, based on the Oxford Science Park, UK, is a drug development company focussed on precision medicine for cancer. It is a spin-out of Oxford University and has secured a number of exclusive licence agreements with pharmaceutical companies, including Astra Zeneca. Celleron’s precision medicine approach is supported by a companion diagnostic biomarker platform, which allows new drugs to be tailored to responsive tumours. Celleron has two Phase 2 clinical assets: CXD101 is a novel dual mechanism HDAC inhibitor which has unique immuno-modulatory effects in tumour cells, and CXD201 represents a new type of topoisomerase inhibitor.
Download the Press Release here: